Neonatal liver failure (NLF) or neonatal acute liver failure is diagnosed in infants with loss of vital liver functions and coagulopathy. Presence of hepatic cirrhosis and lack of encephalopathy do not preclude a diagnosis of NLF. This condition is a common indication for liver transplantation.
1 Gestational alloimmune liver disease (GALD) presenting as neonatal hemochromatosis (NH) is a major cause of NLF. This clinically distinct disease of unclear etiology is characterized by NLF with extrahepatic siderosis. 1 The disease is thought to be an alloimmune liver injury in the fetus mediated by immunoglobulin G (IgG) to the hepatocyte antigen. 2 Recently, exchange transfusion (ET) and intravenous immunoglobulin (IVIG) have been shown to rescue these infants from liver transplantation with improved prognosis. 3 Our case report highlights the dilemma the clinician faces in treating severe hyperbilirubinemia with a high direct component in the absence of established guidelines for phototherapy, ET, and IVIG.
Case
A female baby was born at 32 2/7 weeks' gestation to a 35-yearold G3Ab2 Caucasian mother with premature onset of labor by cesarean section for nonreassuring fetal heart rate. Her prenatal screening laboratory tests were negative; she was noted to be a chronic cigarette smoker with no history of alcohol use. She was on methadone during pregnancy with a urine toxicology screen positive for cocaine a month prior to delivery. Maternal history was significant for hypothyroidism, depression, hypertension, anemia, gastric ulcer, endometriosis, cholecystectomy, and a motor vehicle accident. She had a history
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Neonatal liver failure (NLF) is a rare diagnosis but carries with it significant risks of mortality and morbidity. high serum iron, low total iron binding capacity, and high transferrin saturation were noted with repeated abnormal coagulation screens. DIC persisted for 2 weeks with infant receiving multiple fresh frozen plasma and platelet transfusions prior to normalization of coagulation profile. Abdominal ultrasound demonstrated enlarged liver with no focal masses and no dilatation of intrahepatic biliary ducts. The spleen was enlarged for age and the rest of the organs were normal. Ventricles were normal on head ultrasound with no hemorrhage. Serial echocardiograms revealed normal cardiac anatomy and function. Magnetic resonance imaging of the abdomen demonstrated signal intensity of the liver less than that of the skeletal muscle, consistent with hemochromatosis of the liver. A mucosal biopsy was planned but had to be deferred due to poor yield and improving liver function, after consultation with the transplant center.
Convalescent Care
DIC resolved and LFTs improved over time (►Table 2). Infant was on a high calorie enteral diet (30 Kcal/oz) for failure to thrive at discharge, later requiring a percutaneous gastrostomy tube at 7 months of age. She was found to have bilateral hearing impairment at mid to high frequencies on BAER follow-up. Infant was followed in the neurodevelopmental clinic at our institute on a regular basis after discharge. At her 29-month assessment, using CAT/CLAMS (clinical adaptive test/clinical linguistic and auditory milestone scale), she had a developmental quotient of 90 (normal !85).
Discussion
Though a definitive diagnosis could not be established in this neonate with NLF, intrauterine growth restriction, prematurity, and hyperferritinemia with abnormal iron status may be suggestive of GALD-NH. Hepatic siderosis, as seen in this infant, can be present in many other causes of NLF. Evidence of extrahepatic siderosis, such as in the exocrine pancreas, minor salivary glands, and the respiratory tree besides the liver, 5 could not be documented. Notably, the infant had elevated tyrosine levels and persistent patency of ductus venosus both seen in GALD-NH. 1 GALD is thought to be an alloimmune liver injury in the fetus, mediated by maternal IgG antibodies directed against the fetal hepatocytes.
2 The antigen appears to be a hepatocyte-specific protein uniquely expressed by the fetal hepatocytes; once sensitized to fetal antigen, reactive IgG is transferred to the fetus activating the complement pathway, resulting in hepatocyte injury, a defining feature of GALD. GALD has emerged as one of the commonest etiologies of NLF (60-90%). 6 However, non-GALD etiology of NLF should be considered in the diagnosis and systematic workup of these infants. The prognosis for untreated NLF is generally poor with many infants requiring liver transplantation. In our infant, due to additional complications of prematurity, growth restriction and multiorgan failure, liver transplantation was not an immediate consideration. A therapeutic regimen of ET followed by IVIG has been introduced to eliminate suspected alloantibodies inducing GALD-NH and has been shown to reduce the need for liver transplantation. 3 Administration of IVIG followed by ET has been described on day 25 after birth in an infant with NH, in addition to chelation-antioxidant therapy from day 10.
7
The combination of ET and IVIG, as in our infant, may help in physical removal of alloantibodies from the neonatal circulation and have an immunomodulatory effect.
In the largest case series published to date, ET/IVIG appears to improve outcome and reduce the need for liver transplantation. 3 In the same case series, ET/IVIG was administered at a mean of 15 AE 9 days and only six infants received DVET. 3 The case that we have presented is unique in several aspects. The infant received multiple DVETs/IVIG all in the first week of life based on American Academy of Pediatrics (AAP)-recommended bilirubin guidelines. 8 The AAP recommends not subtracting direct bilirubin from the total bilirubin measurements. However, if the direct bilirubin is >50%, no good data exist to provide guidance. 8 Hence, we decided to proceed with ET/IVIG in this case with a strong suspicion for GALD. Infants with NLF may be extremely sick with total bilirubin values frequently exceeding 25 mg/dL. Though there is a high direct component, the treatment protocol for these infants follows AAP hyperbilirubinemia guidelines based on total bilirubin values.
8 Condition-specific threshold values for bilirubin-induced neurologic dysfunction (BIND) have not been identified and optimal operational thresholds for treatment are yet to be delineated. 9 In population-based studies, the risk of chronic bilirubin encephalopathy or kernicterus varied from 1 in 17.6 in Canada 9,10 to 1 in 16.2 in Denmark 9,11 for a total serum bilirubin level >25 mg/dL. In suspected GALD, ongoing liver injury from maternal alloantibodies may contribute to rising bilirubin, leading to rebound hyperbilirubinemia after ET necessitating repeated ETs. Due to high risk of BIND in immune jaundice, intensive phototherapy was continued in this infant for the first 2 weeks, in spite of a predominantly direct component. IVIG infusions were administered 2 to 3 mg/dL below the ET values of around 20 mg/dL. A more rapid normalization of clotting studies was noted following multiple DVETs (►Table 2), suggesting an immune etiology. The infant had essentially normal liver function by 6 months of age. We propose that earlier administration of IVIG and ET performed in the first week of life not only reduces the morbidity from liver injury and multiorgan failure but also helps in preservation and faster recovery of liver function over time. In this infant, we strived to keep total bilirubin values 20 mg/dL, as the goal to decrease potential for BIND. The infant had bilateral hearing impairment found typically in infants with hyperbilirubinemia; however, her neurodevelopmental assessment at 29 months was reassuring.
To conclude, NLF is a potentially life-threatening condition with a few established treatment guidelines. GALD-NH should be suspected in neonates presenting in liver failure at birth. Along with supportive therapy for NLF, earlier ET and IVIG may help to improve prognosis, decrease incidence of BIND and need for liver transplantation in these infants. Due to the rarity of this diagnosis, pooling of data and large multicenter analyses are required to formulate management protocols for NLF.
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